MagnetisMM-20: Priming Myeloma Tumor Cells for the Bispecific Bout
December 14th 2024Results of a small study presented at the 66th American Society of Hematology Annual Meeting & Exposition suggest combining the bispecific elranatamab with the proteasome inhibitor carfilzomib can bring responses even in patients with stage III disease.